Jazz Pharmaceuticals plc — Director's Dealing 2013

Jan 11, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2013-01-09

Reporting Person: ENRIGHT PATRICK G (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-01-09	Ordinary Shares	S	5783	$56.5164	Disposed	1677857	Indirect
2013-01-09	Ordinary Shares	S	117	$56.5165	Disposed	33635	Indirect
2013-01-10	Ordinary Shares	S	35216	$56.5244	Disposed	1642641	Indirect
2013-01-10	Ordinary Shares	S	706	$56.5246	Disposed	32929	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	2250	Direct

Footnotes

F1: Securities were sold pursuant to a 10b5-1 trading plan.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.50 to $56.61, inclusive. The reporting person undertakes to provide to Jazz Pharmaceuticals plc, any security holder of Jazz Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.50 to $56.61, inclusive. The reporting person undertakes to provide to Jazz Pharmaceuticals plc, any security holder of Jazz Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.50 to $56.66, inclusive. The reporting person undertakes to provide to Jazz Pharmaceuticals plc, any security holder of Jazz Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.50 to $56.66, inclusive. The reporting person undertakes to provide to Jazz Pharmaceuticals plc, any security holder of Jazz Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F6: The reporting person disclaims beneficial ownership of the securities of Jazz Pharmaceuticals plc held by Longitude Venture Partners, L.P. and Longitude Capital Associates, L.P., except to the extent of his pecuniary interest therein.

F7: These restricted stock units were granted pursuant to Jazz Pharmaceuticals plc's 2007 Equity Incentive Plan on August 9, 2012. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units will vest in full on August 9, 2013.